ASCO: Novartis presents positive data from landmark Phase III NATALEE in EBC

2 June 2023

Swiss pharma giant Novartis (NOVN: VX) kicked off its 2023 American Society of Clinical Oncology (ASCO) presentations today, with much anticipated positive primary endpoint data from the pivotal Phase III NATALEE trial on Kisqali (ribociclib) in early breast cancer (EBC).

These show that Kisqali plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2% in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (HR=0.748; 95% CI: 0.618, 0.906; p=0.0014) along with a consistent, clinically-meaningful invasive disease-free survival (iDFS) benefit across key pre-specified subgroups.

Kisqali, a CDK4/6 inhibitor, is the first and only to show consistent, clinically-meaningful results across a broad population of early breast cancer (EBC) patients, said Novartis, which now plans to submit these Phase III data to regulatory authorities in the USA and Europe before end of year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK